AtaiBeckley Joins Nasdaq Biotech Index, Capping Transformative Year

NEW YORK, NY – December 23, 2025 – In a move that underscores a year of significant strategic growth, AtaiBeckley N.V. (NASDAQ: ATAI) has been added to the prestigious NASDAQ Biotechnology Index (NBI). The clinical-stage biopharmaceutical company, a prominent player in the emerging field of psychedelic and related therapies for mental health, announced that its inclusion became effective prior to the market opening on Monday, December 22, 2025.

This milestone serves as a capstone to what the company leadership describes as a defining year. Inclusion in the NBI is not merely symbolic; it signifies that a company has met rigorous standards for market capitalization, trading volume, and public seasoning. For AtaiBeckley, it represents a powerful validation from the financial markets and places it among the leading biotechnology and pharmaceutical firms tracked by one of the sector's most important benchmarks. This development is expected to increase the company's visibility among institutional investors and index funds that use the NBI as a guide for their investment strategies, potentially boosting stock liquidity and stability.

A Year of Strategic Transformation

2025 has indeed been a period of profound transformation for the company. The current AtaiBeckley is the product of a major strategic combination completed in November 2025 between atai Life Sciences and Beckley Psytech Limited. This merger consolidated two of the leading pipelines in the commercial-stage development of psychedelic-based treatments, creating a more robust entity with a diverse portfolio of therapeutic candidates. The goal was to deepen leadership in what the company calls “next-generation mental health therapeutics.”

Further bolstering its foundation, the company successfully raised approximately $300 million in capital during the year. This substantial financial runway is critical for any clinical-stage biopharmaceutical firm, as it fuels the costly and lengthy process of research, development, and late-stage clinical trials required to bring novel drugs to market. The successful capital raise in a challenging economic environment speaks to strong investor belief in the company’s mission and pipeline.

“2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation,” said Srinivas Rao, Chief Executive Officer of AtaiBeckley, in a statement. He highlighted the capital raise, the strategic merger, and the advancement of multiple clinical programs. Rao also pointed to the company’s anticipated domiciliation to the United States, expected around the end of the year, as another key step in its corporate evolution. “As we look ahead, AtaiBeckley is entering a pivotal phase and is well positioned to translate scientific leadership into long-term value for both patients and shareholders, as our recent addition to the NBI further validates,” he added.

The Significance of NBI Inclusion

The NASDAQ Biotechnology Index is a closely watched barometer for the health and performance of the biotechnology sector. It is designed to track the performance of companies listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical. Its constituents are selected annually based on strict eligibility criteria, ensuring that the index is composed of established and actively traded companies.

For a firm like AtaiBeckley, operating in the innovative but still-nascent field of psychedelic medicine, joining the NBI is a significant leap into the mainstream. It places the company on the same stage as more established biotech giants, exposing it to a wider universe of investment managers and institutional funds that are mandated to track or benchmark against the index. This can lead to a more stable and diverse investor base, moving beyond early-stage venture capital and specialized funds to include larger, more conservative financial institutions. The inclusion effectively serves as a third-party endorsement of the company's scale, governance, and market relevance.

Advancing a New Generation of Mental Health Therapies

At the heart of AtaiBeckley's strategy is a clinical pipeline aimed at addressing some of the most challenging areas in mental healthcare. The company's mission is to develop treatments that are not only effective and rapid-acting but also convenient enough to integrate seamlessly into existing healthcare systems. This focus on commercial scalability and patient access is a key differentiator in the field.

The company is currently advancing several novel therapies through Phase 2 clinical trials, a critical stage where the efficacy and safety of a drug are tested in patients. These programs include:

• BPL-003 (mebufotenin benzoate): A novel nasal spray formulation of a short-acting psychedelic compound being investigated for Treatment-Resistant Depression (TRD). The goal is to provide a rapid therapeutic effect with a shorter, more manageable in-clinic experience compared to other psychedelic treatments.

• VLS-01 (DMT buccal film): Another candidate for TRD, this therapy uses a different compound, DMT, delivered via an oral film. This innovative delivery method is designed to provide a controlled and predictable psychedelic experience, potentially making the treatment more accessible.

• EMP-01 ((R)-MDMA HCI): This compound is a specific enantiomer of MDMA being developed for Social Anxiety Disorder (SAD), a condition with significant unmet needs. The therapy aims to leverage the pro-social and empathogenic effects of MDMA to enhance psychotherapy.

Beyond these headline programs, AtaiBeckley is also investing in the future with a drug discovery program focused on identifying novel, non-hallucinogenic agonists of the 5-HT2A serotonin receptor. This research could unlock new treatments for conditions like opioid use disorder and TRD without the subjective psychedelic effects, potentially broadening the patient population and simplifying the treatment paradigm significantly. This dual strategy of advancing both psychedelic and non-psychedelic compounds showcases a pragmatic and comprehensive approach to tackling complex mental health disorders.